to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
Return to Top
Search Result Details
Back to Search Results
This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
Soluble CD16 in the treatment of murine lupus nephritis.
Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B.
Modulation of renal disease in MRL/lpr mice by pharmacologic inhibition of inducible nitric oxide synthase.
Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid.
Impact of estrogen receptor deficiency on disease expression in the NZM2410 lupus prone mouse.
Impact of Fli-1 transcription factor on autoantibody and lupus nephritis in NZM2410 mice.
Multiple Autoantibodies Display Association with Lymphopenia, Proteinuria, and Cellular Casts in a Large, Ethnically Diverse SLE Patient Cohort.
Endothelial nitric oxide synthase reduces crescentic and necrotic glomerular lesions, reactive oxygen production, and MCP1 production in murine lupus nephritis.
Modulation of renal disease in autoimmune NZB/NZW mice by immunization with bacterial DNA.
Effect of late modulation of nitric oxide production on murine lupus.
Effects of complement factor D deficiency on the renal disease of MRL/lpr mice.
Decreased expression of the Ets family transcription factor Fli-1 markedly prolongs survival and significantly reduces renal disease in MRL/lpr mice.
Inducible nitric oxide synthase inhibitor SD-3651 reduces proteinuria in MRL/lpr mice deficient in the NOS2 gene.
Transplantation of umbilical cord mesenchymal stem cells alleviates lupus nephritis in MRL/lpr mice.
Allogenic mesenchymal stem cell transplantation ameliorates nephritis in lupus mice via inhibition of B-cell activation.
Novel mechanism for estrogen receptor alpha modulation of murine lupus.
Camptothecin and Topotecan, Inhibitors of Transcription Factor Fli-1 and Topoisomerase, Markedly Ameliorate Lupus Nephritis in (NZB × NZW)F1 Mice and Reduce the Production of Inflammatory Mediators in Human Renal Cells.
Targeting glycosphingolipid metabolism as a potential therapeutic approach for treating disease in female MRL/lpr lupus mice.